1. Home
  2. SILC vs IMUX Comparison

SILC vs IMUX Comparison

Compare SILC & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Silicom Ltd

SILC

Silicom Ltd

HOLD

Current Price

$42.90

Market Cap

259.1M

Sector

Technology

ML Signal

HOLD

Logo Immunic Inc.

IMUX

Immunic Inc.

HOLD

Current Price

$14.91

Market Cap

209.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SILC
IMUX
Founded
1987
2016
Country
Israel
United States
Employees
N/A
66
Industry
Computer Manufacturing
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
259.1M
209.2M
IPO Year
2002
2013

Fundamental Metrics

Financial Performance
Metric
SILC
IMUX
Price
$42.90
$14.91
Analyst Decision
Hold
Strong Buy
Analyst Count
1
6
Target Price
N/A
$36.00
AVG Volume (30 Days)
164.5K
167.0K
Earning Date
04-30-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
38.00
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$17.17
N/A
Revenue Next Year
$12.28
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$13.34
$0.51
52 Week High
$52.95
$15.84

Technical Indicators

Market Signals
Indicator
SILC
IMUX
Relative Strength Index (RSI) 48.80 59.86
Support Level $38.07 $0.74
Resistance Level $51.05 $15.81
Average True Range (ATR) 4.48 0.82
MACD -0.18 -0.17
Stochastic Oscillator 31.99 53.80

Price Performance

Historical Comparison
SILC
IMUX

About SILC Silicom Ltd

Silicom Ltd is engaged in designing, manufacturing, marketing, and supporting high-performance networking and data infrastructure solutions for a broad range of servers, server-based systems, and communications devices. Its product categories consist of Server Adapters, Edge Networking Solutions, Switches, Edge AI Solutions, Edge Networking Accessories, 4G 5G Products, FPGA-Based Cards, and Others. Its geographic areas are the USA, North America - other, Israel, Europe, and Asia-Pacific. It derives a majority of its revenue from the USA.

About IMUX Immunic Inc.

Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.

Share on Social Networks: